Holen Sie sich die Stockscreener-App
0.973
0.18%
-0.0018
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TPST?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$0.9748
Offen:
$0.98
24-Stunden-Volumen:
94,064
Relative Volume:
0.54
Marktkapitalisierung:
$15.55M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-43.10M
KGV:
-0.1567
EPS:
-6.2098
Netto-Cashflow:
$-26.38M
1W Leistung:
-10.73%
1M Leistung:
-23.39%
6M Leistung:
-32.66%
1J Leistung:
-73.56%
1-Tages-Spanne:
$0.96
$1.00
1-Wochen-Bereich:
$0.95
$1.0993
52-Wochen-Spanne:
$0.95
$6.115
Tempest Therapeutics Inc Stock (TPST) Company Profile
Firmenname
Tempest Therapeutics Inc
Sektor
Branche
Telefon
415-798-8589
Adresse
2000 SIERRA POINT PARKWAY, BRISBANE
Compare TPST vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TPST
Tempest Therapeutics Inc
|
0.973 | 15.55M | 0 | -43.10M | -26.38M | -6.2098 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tempest Therapeutics Inc Stock (TPST) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-22 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-04-10 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-04-10 | Herabstufung | Scotiabank | Sector Outperform → Sector Perform |
| 2024-03-14 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-02-08 | Eingeleitet | Jefferies | Buy |
Tempest Therapeutics Inc Aktie (TPST) Neueste Nachrichten
Tempest Therapeutics (NASDAQ: TPST) registers 2.43M shares for resale tied to warrants - Stock Titan
[EFFECT] Tempest Therapeutics, Inc. SEC Filing - Stock Titan
Tempest Therapeutics (NASDAQ: TPST) seeks shareholder vote to amend charter - Stock Titan
Enterprise value to revenue forward of Tempest Therapeutics, Inc. – NASDAQ:TPST - TradingView
Tempest Therapeutics (TPST) Rallies Modestly as Stock Holds Above Key SupportMomentum ETF - dars.gov.et
Tempest Therapeutics Registers 2.43 Million Shares for Resale - Moomoo
Form S-3 Tempest Therapeutics Inc For: 26 June By Investing.com - Investing.com Nigeria
TPST Forecast — Price Target — Prediction for 2027 - TradingView
TPST: Selling Stockholders Plan to Offer 2.43 Million Shares - GuruFocus
Tempest Therapeutics (NASDAQ: TPST) registers 2.43M shares from warrants - Stock Titan
3OS0 Forecast — Price Target — Prediction for 2027 - TradingView
Price to earnings forward of Tempest Therapeutics, Inc. – NASDAQ:TPST - TradingView
Price to sales forward of Tempest Therapeutics, Inc. – NASDAQ:TPST - TradingView
Enterprise value to revenue forward of Tempest Therapeutics, Inc. – LS:A41556 - TradingView
Price to sales forward of Tempest Therapeutics, Inc. – LS:A41556 - TradingView
Enterprise value to EBITDA forward of Tempest Therapeutics, Inc. – NASDAQ:TPST - TradingView
Tempest Therapeutics, Inc. Actuals & Estimates (NASDAQ:TPST) - TradingView
Price to earnings forward of Tempest Therapeutics, Inc. – LS:A41556 - TradingView
Enterprise value to EBIT forward of Tempest Therapeutics, Inc. – NASDAQ:TPST - TradingView
Tempest Therapeutics Inc (TPST) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Price to book forward of Tempest Therapeutics, Inc. – NASDAQ:TPST - TradingView
Tempest Therapeutics Inc (TPST) Valuation: PE, PB & Fair Value Analysis - TradingKey
Form 4 Tempest Therapeutics Inc For: 23 June By Investing.com - Investing.com Nigeria
Tempest Therapeutics CEO Matthew Angel acquires $500,001 in stock By Investing.com - Investing.com South Africa
Tempest Therapeutics CEO Matthew Angel acquires $500,001 in stock - Investing.com
CEO-linked entity boosts Tempest (TPST) stake with stock and new warrants - Stock Titan
Tempest Therapeutics shareholders approve issuance of up to 4.2 million shares By Investing.com - Investing.com South Africa
Form 8K Tempest Therapeutics Inc For: 23 June By Investing.com - Investing.com South Africa
TPST PE Ratio & Valuation, Is TPST Overvalued - Intellectia AI
Tempest Therapeutics shareholders approve issuance of up to 4.2 million shares - Investing.com
Tempest Therapeutics (NASDAQ: TPST) holders approve warrant share issuances - Stock Titan
Tempest Therapeutics, Inc. 8-K Filing – Special Meeting Results, Common Stock Issuance Approved, Company Details (June 2026) – Minichart - Minichart
Tempest Therapeutics Inc (TPST) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Tempest Therapeutics Inc (TPST) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Tempest Therapeutics Inc (TPST) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Tempest Therapeutics Inc (TPST) Institutional Confidence - TradingKey
Director at Tempest Therapeutics (TPST) receives 25,000 stock options grant - Stock Titan
[Form 3] Tempest Therapeutics, Inc. Initial Statement of Beneficial Ownership - Stock Titan
Tempest Therapeutics (TPST) Climbs 2.8% as Stock Approaches Critical $1.34 Resistance LevelLow Risk Entry Stocks - newsline.com
Tempest Therapeutics Inc (TPST) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Tempest Therapeutics Inc (TPST) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Tempest Therapeutics Inc (TPST) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Tempest Therapeutics | S-8 POS: S-8 POS - Moomoo
Tempest Therapeutics (TPST) Edges Higher as Stock Tests Resistance Near $1.34EMA Signal - newsline.com
Director Richey William Drake reports 2,000 TPST shares on Form 3 - Stock Titan
Tempest Therapeutics (TPST) director awarded 25,000 stock options at $1.27 strike - Stock Titan
Warrant share approvals on ballot at Tempest Therapeutics (NASDAQ: TPST) - Stock Titan
Tempest Therapeutics appoints two directors to board By Investing.com - Investing.com India
Tempest Therapeutics Announces CFO Transition and Board Changes - TipRanks
Tempest Therapeutics appoints two directors to board - Investing.com UK
Finanzdaten der Tempest Therapeutics Inc-Aktie (TPST)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.64%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):